Physician profile
Leonid E Tafler
NPI 1932237146
$1,749.96
in general payments reported to CMS, 2019-2025
12 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $80.44 · 2021: $239 · 2022: $378 · 2023: $375 · 2024: $306 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.66 | 2019-2025 | Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.63 | 2021-2023 | Xifaxan |
| Gilead Sciences, INC. | $201.41 | 2021-2022 | |
| Lilly USA, LLC | $127.14 | 2024 | Mounjaro, Zepbound |
| Pfizer INC. | $125.00 | 2024 | |
| Novo Nordisk INC | $94.54 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $38.82 | 2024-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $37.46 | 2020 | |
| Fidia Pharma USA INC. | $23.00 | 2020 | |
| Pacira Therapeutics, INC. | $19.98 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.87 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Tafler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.